INTRODUCTION:
Cervical length surveillance (CLS) can identify women at increased risk for recurrent spontaneous preterm birth (sPTB) based on transvaginal ultrasound (TVUS). CLS between 24 and 28 weeks is at times performed to administer corticosteroids to women considered at risk of recurrent sPTB. Primary objective was to evaluate the relationship between cervical shortening between 24 and 28 weeks and recurrent sPTB.
METHODS:
Retrospective cohort study of women with history of singleton sPTB between 24 and 32 weeks, who underwent CLS between 24 and 28 weeks at Lehigh Valley Hospital from 2012-2018. IRB approval was obtained. Exposure of interest was cervical shortening less than 2.5 cm. Primary outcome was delivery less than 37 weeks. Secondary outcomes included rate of antenatal interventions and interval between betamethasone administration and delivery.
RESULTS:
3,545 women underwent TVUS for CLS. 118 (3.3%) with CLS between 24 and 28 weeks met inclusion criteria. Cervical shortening was identified in 16 (13.6%) women. Primary outcome was similar among women with short versus normal cervical length. After adjustment, sPTB less than 37 weeks did not correlate with cervical shortening between 24 and 28 weeks, but with clinical preterm labor (AOR 4.02, 95% CI 1.2–13.4; P=.02).
CONCLUSION:
In our population, the risk of sPTB less than 37 weeks was not predicted by the diagnosis of cervical shortening between 24 and 28 weeks. Our data suggest that the clinical presentation of spontaneous preterm labor, not CLS, is the significant risk factor for sPTB in a subsequent pregnancy for women with a history of sPTB.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.